Phase II Study of Biweekly Plitidepsin as Second-Line Therapy for Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

The objective of this exploratory, open-label, single-arm, phase II clinical trial was to evaluate plitidepsin (5 mg/m(2)) administered as a 3-hour continuous intravenous infusion every two weeks to patients with locally advanced/metastatic transitional cell carcinoma of the urothelium who relapsed/...

Descripción completa

Detalles Bibliográficos
Autores principales: Dumez, Herlinde, Gallardo, Enrique, Culine, Stephane, Galceran, Joan Carles, Schöffski, Patrick, Droz, Jean P., Extremera, Sonia, Szyldergemajn, Sergio, Fléchon, Aude
Formato: Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International 2009
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2763111/
https://www.ncbi.nlm.nih.gov/pubmed/19841725
http://dx.doi.org/10.3390/md7030451

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2763111/
https://www.ncbi.nlm.nih.gov/pubmed/19841725
http://dx.doi.org/10.3390/md7030451

Ejemplares similares